Coelewij L, Adriani M, Dönnes P, Waddington KE, Ciurtin C, et al. (2024). Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity. Clin Immunol 267: 110339. PMID: 39137826
Correia C, Christoffersson J, Tejedor S, El-Haou S, Matadamas-Guzman M, et al. (2024). Enhancing Maturation and Translatability of Human Pluripotent Stem Cell-Derived Cardiomyocytes through a Novel Medium Containing Acetyl-CoA Carboxylase 2 Inhibitor. Cells 13(16). PMID: 39195229
Mebrahtu A, Laurén I, Veerman R, Akpinar GG, Lord M, et al. (2024). A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice. Nat Commun 15(1): 9542. PMID: 39500897
Tejedor S, Wågberg M, Correia C, Åvall K, Hölttä M, et al. (2024). The Combination of Vascular Endothelial Growth Factor A (VEGF-A) and Fibroblast Growth Factor 1 (FGF1) Modified mRNA Improves Wound Healing in Diabetic Mice: An Ex Vivo and In Vivo Investigation. Cells 13(5). PMID: 38474378
Oppong AE, Coelewij L, Robertson G, Martin-Gutierrez L, Waddington KE, et al. (2024). Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity. iScience 27(3): 109225. PMID: 38433900
Peng J, Dönnes P, Ardoin SP, Schanberg LE, Lewandowski L, et al. (2024). Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis Rheumatol 76(3): 455-468. PMID: 37786302
Laurén I, Havervall S, Ng H, Lord M, Pettke A, et al. (2022). Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. Immun Inflamm Dis 10(4): e595. PMID: 35349756
Havervall S, Ng H, Jernbom Falk A, Greilert-Norin N, Månberg A, et al. (2022). Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. J Intern Med 291(1): 72-80. PMID: 34459525; PMCID: PMC8661920.
Assenhöj M, Eriksson P, Dönnes P, Ljunggren SA, Marcusson-Ståhl M, et al. (2021). Protein interaction, monocyte toxicity and immunogenic properties of cerium oxide crystals with 5% or 14% gadolinium, cobalt oxide and iron oxide nanoparticles – an interdisciplinary approach. Nanotoxicology 15(8): 1035-1058. PMID: 34468264.
Peng J, Jury EC, Dönnes P, Ciurtin C (2021). Machine Learning Techniques for Personalised Medicine Approaches in Immune-Mediated Chronic Inflammatory Diseases: Applications and Challenges. Front Pharmacol 12: 720694. PMID: 34658859; PMCID: PMC8514674.
Mangsbo SM, Havervall S, Laurén I, Lindsay R, Jernbom Falk A, et al. (2021). An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses. PLoS One 16(9): e0258041. PMID: 34591918; PMCID: PMC8483319.
Coelewij L, Waddington KE, Robinson GA, Chocano E, McDonnell T, et al. (2021). Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Arterioscler Thromb Vasc Biol 41(4): 1446-1458. PMID: 33535791; PMCID: PMC7610443.
Hässler S, Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S,
Aktas O, Auer M, Avouac J, Birchler M, Bouhnik Y, Brocq O, Buck-Martin D, Cadiot
Hässler S, Bachelet D, Duhaze J, Szely N, Gleizes A, et al. (2020). Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Med 17(10): e1003348.PMID: 33125391; PMCID: PMC7598520.
Robinson GA, Peng J, Dönnes P, Coelewij L, Naja M, et al. (2020). Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatol 2(8): e485-e496. PMID: 32818204; PMCID: PMC7425802.
Waddington KE, Papadaki A, Coelewij L, Adriani M, Nytrova P, et al. (2020). Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ. Front Immunol 11: 1527. PMID: 32765529; PMCID: PMC7380268.
Synnergren J, Vukusic K, Dönnes P, Jonsson M, Lindahl A, et al. (2020). Transcriptional sex and regional differences in paired human atrial and ventricular cardiac biopsies collected in vivo. Physiol Genomics 52(2): 110-120.
PMID: 31869284.
Bachelet D, Albert T, Mbogning C, Hässler S, Zhang Y, et al. (2019). Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. PLoS One 14(6): e0218258. PMID: 31194850; PMCID:
PMC6564000.
Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, et al. (2019). Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Semin Arthritis Rheum 48(6): 967-975.PMID: 30420245.
Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, et al. (2019). Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. J Neuroimmunol 326: 19-27. PMID: 30447419.
Delsing L, Dönnes P, Sánchez J, Clausen M, Voulgaris D, et al. (2018). Barrier Properties and Transcriptome Expression in Human iPSC-Derived Models of the Blood-Brain Barrier. Stem Cells 36(12): 1816-1827.PMID: 30171748.
Bitoun S, Nocturne G, Ly B, Krzysiek R, Roques P, et al. (2018). Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann Rheum Dis 77(10): 1463-1470. PMID: 29936438.
Adriani M, Nytrova P, Mbogning C, Hässler S, Medek K, et al. (2018). Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients. JCI Insight 3(11). PMID: 29875313; PMCID:
PMC6124413.
Schubert B, Schärfe C, Dönnes P, Hopf T, Marks D, et al. (2018). Population-specific design of de-immunized protein biotherapeutics. PLoS Comput Biol 14(3): e1005983.PMID: 29499035; PMCID:
PMC5851651.
Link J, Ramanujam R, Auer M, Ryner M, Hässler S, et al. (2017). Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS One 12(2): e0170395.PMID: 28170401; PMCID: PMC5295710.
Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, et al. (2016). Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. PLoS One 11(11): e0162752. PMID: 27806057; PMCID: PMC5091903.